other material
confidence high
sentiment positive
materiality 0.65
Zentalis reports 39% ORR, 7.3-month median PFS for azenosertib+paclitaxel in PROC at ASCO
Zentalis Pharmaceuticals, Inc.
- Phase 1b MUIR trial: all-comer PROC (n=46), ORR 39.1%, CBR 58.7%, median DOR 5.6 mo, median PFS 7.3 mo.
- At 250 mg intermittent dose (n=12): ORR 50.0%, median DOR 9.2 mo, median PFS 5.5 mo, manageable safety.
- Cyclin E1-positive (ORR 41.4%) and -negative (ORR 35.7%) patients showed comparable activity.
- Grade ≥3 TRAEs: neutropenia 30.4%, anemia 19.6%; one Grade 5 sepsis event previously reported.
- Data supports combo expansion; core focus remains azenosertib monotherapy in Cyclin E1+ PROC.